The low co-occurrence of mutations of KRAS or BRAF with PIK3CA in our cohort suggests unique oncogenic pathways that may be affected by racial and geographical distribution and underscore the heterogeneity of CRC at both clinical and molecular levels. The gene discussed is KRAS; the disease is colorectal carcinoma.